耐药菌感染的噬菌体治疗专利技术

耐药菌,尤其是多重耐药菌的出现和持续进化给人类健康带来了巨大的威胁。在抗生素逐渐失去特效作用的情况下,科学界和医药界又把眼光重新投向了抗菌的天然生物-噬菌体,并在一些研究中证明了噬菌体可以作为新的武器去替代抗生素治疗耐药菌感染。通过对噬菌体治疗及衍生的裂解酶治疗的世界专利申请进行统计及分析,获得了专利发展趋势、申请人分布特点及主要专利申请人等信息,详细分析了噬菌体及裂解酶治疗的主要专利技术路线和研发热点。     

噬菌体治疗细菌性感染的进展

噬菌体是自然界中广泛存在的细菌病毒,作为细菌的天然杀手,在细菌性感染尤其是多重耐药菌感染的治疗方面具有抗生素无法比拟的优势。综述了利用活噬菌体治疗细菌性感染的早期研究及近几年的初步临床试验结果、利用噬菌体裂解酶治疗细菌性感染的最新进展,指出了噬菌体治疗真正得以应用所面临的主要障碍并综述分析了一些具有一定可行性的解决方案,以期为噬菌体治疗的研究和应用提供参考,并推动噬菌体治疗研究的进一步发展。     

噬菌体及其裂解酶控制金黄色葡萄球菌的研究进展

近70年来,由于抗生素的广泛使用,耐药金黄色葡萄球菌不断出现。美国1999～2005年因感染耐甲氧西林金黄色葡萄球菌（MRSA）而入院的患者增加1倍多,其中诊断为败血症的患者增加81．2％。因此,寻找控制耐药菌的新对策十分迫切。目前有望替代抗生素的控菌手段有抗菌肽、噬菌体等。其中,噬菌体的发现早于抗生素,后因抗生素的普及而被忽视。如今,耐药菌株的流行使噬菌体治疗再次受到关注。本文就应用噬菌体及其裂解酶控制金黄色葡萄球菌的研究进展进行综述。     

噬菌体及其裂解酶对细菌生物被膜作用的研究进展

细菌形成的生物被膜,可保护细菌不易被抗生素杀死,这给临床上相应疾病的治疗及医疗器械的消毒带来极大困难。研究表明,噬菌体及其裂解酶对生物被膜有降解作用。噬菌体能清除细菌在有生物活性或无生物活性的介质表面形成的生物被膜。此外,噬菌体裂解酶比如LySMP、肽酶CHAPk、细胞壁溶解酶CWHs等能清除特定的生物被膜,这可能与裂解酶直接溶菌和裂解细菌细胞外基质有关。同时,与抗生素、钴离子、氯等物质联合使用时,噬菌体对生物被膜的清除作用会更强。本文从噬菌体、噬菌体编码的裂解酶、以及它们联合其他物质对细菌生物被膜的作用进行综述,并对其实际应用做了展望。     

噬菌体治疗肺炎克雷伯菌感染的研究进展

随着细菌的进化以及部分抗生素的滥用，耐药细菌的感染已成为21世纪主要的公共卫生挑战之一。其中，耐药肺炎克雷伯菌(Klebsiella pneumoniae)问题尤为突出。噬菌体在治疗耐药细菌感染引起的疾病方面展现出一定的潜力及独特优势，但目前噬菌体治疗尚缺乏统一的临床指导规范。虽然临床上有少数将噬菌体用于治疗肺炎克雷伯菌感染的成功案例，但多数情况下是采用噬菌体配合抗生素疗法，噬菌体在其中的作用仍不明确。本文综合评述国内外研究数据，回顾与噬菌体治疗肺炎克雷伯菌感染相关的数个重点问题，包括噬菌体的特性以及影响其疗效的因素，旨在为肺炎克雷伯菌和其他耐药细菌的噬菌体治疗提供参考。     

噬菌体治疗肺炎克雷伯菌感染的研究进展

肺炎克雷伯菌是肠杆菌科家族中的一员,在各种环境中广泛存在,可导致诸如奶牛乳房炎在内的多种动物疫病,引起人类的肺炎、尿路感染、菌血症、伤口性感染和化脓性脓肿在内的多种临床感染。该菌对抗生素的耐受日趋严重,而且高毒力菌株不断出现,给该菌的防控带来了巨大挑战。噬菌体是一种裂解细菌的病毒,因其具有治疗耐药细菌感染的潜力而备受关注,世界各地均有使用噬菌体成功治疗耐药细菌感染的案例。本文基于国内外对肺炎克雷伯菌及其噬菌体的研究数据,综述了肺炎克雷伯菌的流行病学调查情况和噬菌体在治疗肺炎克雷伯菌感染方面的应用,以期为基于肺炎克雷伯菌噬菌体的抗菌研究和临床应用提供参考。     

高效广谱猪链球菌7型前噬菌体裂解酶的挖掘及活性研究

【目的】噬菌体具有防控耐药性病原菌的抗菌应用潜力,但是有些病原菌噬菌体的获得非常困难,研究发现大多数病原菌存在前噬菌体(prophage),且由前噬菌体编码的裂解酶(endolysin)具有良好的抗菌应用前景,本研究将挖掘猪链球菌前噬菌体及其编码的裂解酶。【方法】通过对GenBank中登录的数株猪链球菌前噬菌体裂解酶的基因信息分析,挖掘出一株猪链球菌7型菌株前噬菌体编码的裂解酶,研究其生物学活性。以猪链球菌7型菌株7917的基因组为模板,采用PCR技术扩增获得裂解酶基因ly7917,将其克隆至质粒pET28a(+)并转化大肠杆菌DH5α细胞,挑选基因序列正确的阳性克隆、抽提质粒、转化表达菌株大肠杆菌BL21,经IPTG诱导可高效表达裂解酶Ly7917。【结果】平板裂解试验结果显示Ly7917具有高效裂菌活性,能够裂解猪链球菌2型高致病力菌株HA9801;浊度递减试验结果显示该裂解酶能够高效裂解猪链球菌2型、7型、9型和马链球菌兽疫亚种参考株、金黄色葡萄球菌(包括耐甲氧西林金黄色葡萄球菌)等多种革兰氏阳性菌。【结论】基于前噬菌体挖掘的裂解酶Ly7917,具有高效广谱裂菌活性,为临床上利用裂解酶治疗耐药菌的混合感染提供了可能。     

一株粪肠球菌噬菌体的分离及其生物学特性研究

目的:利用临床耐药粪肠球菌分离裂解性噬菌体,为应用噬菌体治疗耐药粪肠球菌感染提供基础。方法:利用噬菌斑实验分离噬菌体并观察噬菌斑形态;双层平板培养法测定噬菌体效价、最佳感染复数及一步生长曲线;负染法电镜观察噬菌体形态;蛋白酶K/SDS法提取噬菌体基因组,酶切处理后琼脂糖凝胶电泳分析。结果:分离出一株噬菌体IME-EF1,该噬菌体能裂解多株临床分离的粪肠球菌;电镜观察呈蝌蚪形,最佳感染复数为1;通过绘制一步生长曲线,证明该噬菌体感染后的潜伏期为25 min,爆发期为35 min,裂解量为60 pfu。结论:研究结果表明利用临床分离的耐药粪肠球菌分离裂解性噬菌体是可行的,有望为耐药粪肠球菌的抗生素替代疗法奠定基础。     

复合噬菌体裂解酶对白羽肉鸡肠道菌群结构和肝脏抗氧化酶指标的影响

【背景】噬菌体裂解酶具有良好的安全性与抑菌特性,有望替代抗生素作为一种饲料添加剂应用于改善畜禽肠道菌群和预防动物疾病。【目的】以白羽肉鸡为饲喂对象,分别饲喂复合噬菌体裂解酶与抗生素制剂,评估噬菌体裂解酶对畜禽肠道菌群的影响及其作为替抗饲料添加剂的应用潜能。【方法】以3日龄健康白羽肉鸡为饲喂对象,在基础饲粮上添加由噬菌体裂解酶TSPphg和噬菌体裂解酶MMPphg获得的复合噬菌体裂解酶制剂(200 mg/kg)与50μg/g的金霉素制剂,分别进行比较饲喂管理。利用第三代测序技术对28 d时白羽肉鸡肠道菌群进行高通量测序,借助生物信息学分析肠道菌群多样性和优势菌群(丰度前10)相对丰度,揭示各分组组间与组内差异,并对肝脏主要氧化酶活性进一步比较。【结果】饲喂复合噬菌体裂解酶和金霉素制剂对白羽肉鸡肠道菌群有一定影响,均降低了肠道菌群相对丰度与多样性,而且Shannon指数与空白组相比存在显著差异(P0.05)。优势菌群中,复合噬菌体裂解酶组相较于金霉素组和空白组,拟杆菌门的相对丰度发生了显著上升,而厚壁菌门的相对丰度发生了显著下降(P0.05)。同时,在属水平上,粪杆菌属的相对丰度发生了显著上升,而螺杆菌属的相对丰度发生了显著下降(P0.05),这一趋势与多数替代抗生素产品饲喂家禽后肠道菌群变化趋势类似,更有利于家禽肠道的健康。此外,饲喂复合噬菌体裂解酶组相较于金霉素组和空白组,过氧化氢酶(Catalase,CAT)和超氧化物歧化酶(Superoxide Dismutase,SOD)活性均发生了显著上升(P0.05)。【结论】噬菌体裂解酶能够有效改善畜禽肠道菌群,促进畜禽肠道菌群的微生态健康及提高机体免疫力,将噬菌体裂解酶替代抗生素应用于畜禽养殖具有较好的前景,值得进一步研究。     

一株新型牛源肺炎克雷伯菌噬菌体的分离鉴定

【背景】肺炎克雷伯菌(Klebsiella pneumoniae)是一种广泛分布于环境中的重要致病菌,该菌较高的耐药性致其在养殖业中治疗较为困难。【目的】分离一株裂解性肺炎克雷伯菌噬菌体,对分离株进行生物学特性鉴定和基因组学分析。【方法】使用双层平板法从四川省某奶牛场中分离、纯化出一株裂解性噬菌体,测定其裂解谱、热稳定性、酸碱耐受度、最佳感染复数及一步生长曲线等生物学特性,并进行全基因组的测序及注释分析。【结果】得到一株裂解性肺炎克雷伯菌噬菌体vB_Kpn_B01,该噬菌体拥有透明且无晕环的噬菌斑,热稳定性较高,在极酸或极碱环境下不进行裂解活动,特异性较强,属长尾噬菌体科(Siphoviridae)。vB_Kpn_B01全基因组大小为113 227 bp,GC含量为47.97%。注释结果显示噬菌体拥有149个编码序列和25个tRNAs,不含耐药基因及毒力基因。通过噬菌体的进化树分析发现,该噬菌体为Sugarlandvirus。【结论】vB_Kpn_B01拥有高效的生长特性和对不利环境的低耐受性,拥有裂解宿主菌的必备基因,并不含耐药基因及毒力基因,具有应用于畜牧业中防治多重耐药细菌的潜力。     

噬菌体裂解酶——现状与未来

噬菌体裂解酶是一种由DNA噬菌体基因编码的高特异性酶, 可高效消化细菌细胞壁。革兰氏阳性菌噬菌体裂解酶的结构域相似, 裂解效率高, 与抗生素具协同抗菌作用, 且不易产生耐受性菌株, 抗体等体液因子对裂解酶的裂解活性影响小, 裂解酶作为一种潜在抗感染药物具有重要的研究价值。目前已建立了多种病原菌裂解酶应用的动物模型, 在防控耐药性病原菌感染上取得重要进展。本文就噬菌体裂解酶的抗菌作用进行综述。     

噬菌体治疗——旧概念,新阶段

噬菌体治疗技术由来已久.噬菌体治疗的研究始于上世纪初,之后由于抗生素的出现及其他原因在美国和西欧等国家中断.近年来,全球范围的细菌耐药性使得科学家们重新审视和评估噬菌体治疗技术,显示出巨大潜力.论述噬菌体发现历程及早期研究、人类及动物细菌感染的应用、噬菌体治疗与抗生素的不同之处、存在的问题等,并探讨噬菌体技术可能的发展...     

细菌与噬菌体相互抵抗机制研究进展

噬菌体作为一种侵染细菌的病毒,能够特异性识别宿主细菌。近年来,抗生素的过度使用导致耐药细菌的出现,噬菌体有望成为对抗耐药细菌的新武器。在细菌与噬菌体长期共进化过程中,二者都演化出一系列抵御策略。本文从抑制噬菌体吸附、阻止噬菌体DNA进入、切割噬菌体基因组、流产感染以及群体感应对噬菌体的调控等方面,对细菌抵抗噬菌体的机制以及噬菌体应对细菌的策略进行了综述,同时还列举了细菌和噬菌体相互抵抗机制的检测方法,以期为噬菌体在细菌控制中的应用以及探究细菌抵抗噬菌体的机制提供理论依据。     

Antimicrobial activity of polyphenolic compounds from Spirulina against food-borne bacterial pathogens

Food-borne drug-resistant bacteria have adverse impacts on both food manufacturers and consumers. Disillusionment with the efficacy of current preservatives and antibiotics for controlling food-borne pathogens, especially drug-resistant bacteria, has led to a search for safer alternatives from natural sources. Spirulina have been recognized as a food supplement, natural colorant, and enriched source of bioactive secondary metabolites. The main objectives of this study were to isolate polyphenolic compounds from Spirulina and analyze their antibacterial potential against drug-resistant food-borne bacterial pathogens. We found that fraction B of methanol extract contained a high quantity of polyphenols exhibiting broad spectrum antimicrobial effects against drug-resistant food-borne bacterial pathogens. Potential secondary metabolites, such as benzophenone, dihydro-methyl-phenylacridine, carbanilic acid, dinitrobenzoate, propanediamine, isoquinoline, piperidin, oxazolidin, and pyrrolidine, were identified by gas chromatography and mass spectrophotometry (GCMS). These metabolites are active against both gram-positive and gram-negative pathogens. Our work suggests that phenolic compounds from Spirulina provide a natural and sustainable source of food preservatives for future use.     

Isolation and partial characterization of Salmonella Gallinarum bacteriophage

Infections caused by Salmonella remain a major public health problem worldwide. Animal food products, including poultry meat and eggs, are considered essential components in the individual’s daily nutrition. However, chicken continues to be the main reservoir for Salmonella spp.Poultry farmers use several types of antibiotics to treat pathogens. This can pose a health risk as pathogens can build antibiotic resistance in addition to the possibility of accumulation of these antibiotics in food products. The use of phages in treating poultry pathogens is increasing worldwide due to its potential use as an effective alternative to antibiotics. Phages have several advantages over antibiotics; phages are very specific to target bacteria, less chances of developing secondary infections, and they only replicate at the site of infection.Here we report the isolation of a bacteriophage from chicken feces. The isolated bacteriophage hosts on Salmonella Gallinarum, a common zoonotic infection that causes fowl typhoid, known to cause major losses to poultry sector. The isolated bacteriophage was partially characterized as a DNA virus resistant to RNase digestion with approximately 20 Kb genome. SDS-PAGE analysis of total viral proteins showed at least five major bands (21, 28, 42, 55 and 68 kDa), indicating that this virus is relatively small compared to other known poultry phages. The isolated bacteriophage has the potential to be an alternative to antibiotics and possibly reducing antibiotic resistance in poultry farms.     

The phage P.E1 isolated from hospital sewage reduces the growth of Escherichia coli

This study involves partial characterisation of a lytic bacteriophage P.E₁ against a multi drug-resistant clinical isolate of Escherichia coli, isolated from hospital sewage supply. The phage P.E₁ has showed a narrow host range suitable for its use in phage therapy. Phage showed lytic activity up to 70°C and at alkaline conditions, but at higher acidic conditions its activity decreased. Latent period and burst size of P.E₁ estimated from single-step growth curve was 40 min and 185 plaque-forming units per cell, respectively. The phage P.E₁ reduced the growth of host bacteria during the initial 12?h of infection; however, the host bacteria developed resistance afterwards. During the 24-hour observation period, the bacteriophage could still reduce the growth of its host bacteria evident by lower optical density in the phage-treated samples compared with control. The phage genome was double-stranded DNA and larger than 12?kb in size. Further manipulations of genome and proteins may help to unveil the unique aspects of this phage, to use it in phage therapy against E. coli.     

放线菌来源的糖肽类抗生素的药学机制研究进展

糖肽类抗生素具有较好的抑制革兰氏阳性细菌生长的活性,临床上广泛用于治疗革兰氏阳性细菌导致的严重感染性疾病,也被认为是对抗这类顽固性病原菌的最后一道防线。随着耐药菌的不断涌现,糖肽类抗生素的应用越来越受到限制。本文针对糖肽类抗生素的结构特征与药效关系、生物学活性和病原菌对于它们的耐药机制,以及糖肽类抗生素的生物合成机制及其结构的合成生物学改造等方面进行了概述。最后,对糖肽类抗生素在应用中面临的问题进行了展望。     

Bacteriocin nanoconjugates: boon to medical and food industry

Resistance to antibiotics is an ongoing problem in the biomedical industry. Developing active, alternative drug therapies would reduce our reliance on antibiotics that induce resistance in micro-organisms. To date, bacteriocins and antimicrobial peptides have shown a positive outcome as antibiotic substitutes and synergists apart from phage therapy, antibodies and probiotics. Bacteriocins are proteinaceous antimicrobial peptides synthesized by lactic acid bacteria extensively used as bio-preservatives and alternative to traditional antibiotics to overcome the problem of drug-resistant pathogens. Nonetheless, the use of bacteriocins has several limitations such as limited antimicrobial spectrum, requiring high dose, sensitivity to proteolytic enzymes, etc. Nanoparticles are one of the promising area of research explored to improve antimicrobial spectrum of bacteriocins. This review therefore highlights the recent developments and research pertaining to use of nanoparticles and bacteriocin conjugates to tackle the resistance crisis as well as its applications in food industry.